Danaher Corporation $DHR Shares Sold by Panagora Asset Management Inc.

Key Points

• Panagora Asset Management Inc. has reduced its stake in Danaher Corporation by 33.0%, now owning 7,931 shares worth approximately $1.63 million after selling 3,899 shares in the first quarter.
• Multiple hedge funds, including Consulta Ltd and Canada Pension Plan Investment Board, increased their holdings in Danaher, contributing to institutional investors owning 79.05% of the company.
• Analysts have mixed opinions on Danaher's stock price, with recent target adjustments ranging from $225.00 to $241.00, while the current consensus rating is a "Moderate Buy" with an average price target of $246.35.

Panagora Asset Management Inc. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 33.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,931 shares of the conglomerate's stock after selling 3,899 shares during the period. Panagora Asset Management Inc.'s holdings in Danaher were worth $1,626,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in DHR. GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares in the last quarter. Heck Capital Advisors LLC bought a new position in Danaher in the 4th quarter worth approximately $27,000. Sierra Ocean LLC lifted its stake in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in shares of Danaher in the 1st quarter valued at approximately $31,000. Finally, Dunhill Financial LLC boosted its stake in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after buying an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 1.3%

Danaher stock traded down $2.69 during midday trading on Monday, reaching $197.52. The stock had a trading volume of 2,149,497 shares, compared to its average volume of 4,133,831. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock has a market capitalization of $141.44 billion, a PE ratio of 42.12, a price-to-earnings-growth ratio of 2.79 and a beta of 0.75. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The stock's 50-day simple moving average is $201.93 and its 200 day simple moving average is $199.31.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period last year, the company posted $1.72 earnings per share. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on DHR. Barclays reissued an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Finally, Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.20% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.